LILRB1 and melanoma: What’s more, patients with higher levels of CD8, VISTA, PD-L2, LAG3, ADORA2A, IDO1, IDO2 and ILT2 had markedly improved disease-free survival, suggesting that their expression can be used as a prognostic marker, with high levels being favorable in melanoma (Figure S6).